Critical Data Release Positions Arvinas Shares for Major Move

Arvinas investors are bracing for what could prove to be the most consequential week of the year for the biotechnology firm. The company approaches a pivotal moment with two separate clinical trial readouts for its flagship treatment Vepdegestrant scheduled for presentation at the European Society for Medical Oncology congress, events that could fundamentally reshape the investment case for the stock.

The European oncology community will gather in Berlin from October 17-21, 2025, where Arvinas is slated to disclose crucial clinical findings. The spotlight intensifies on October 20 with the anticipated release of VERITAC-2 Phase 3 trial results, which directly compare Vepdegestrant against Fulvestrant in patients with ESR1-mutated breast cancer. Preceding this, on October 19, the company will present findings from the TACTIVE-N... Read more...